StockNews.AI
MDGL
StockNews.AI
188 days

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

1. Madrigal will announce Q4 and 2024 results on Feb. 26, 2025. 2. Management will host a live webcast to review financial results. 3. Rezdiffra aims to treat MASH, addressing a significant medical need.

Earnings
+3.95%Current Return
VS
+0.62%S&P 500
$331.7902/12 08:04 AM EDTEvent Start
$344.9102/13 03:05 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may indicate positive progress, similar to past successful announcements.

How important is it?

Earnings announcements often directly influence stock performance, particularly for biopharmaceuticals.

Why Short Term?

The immediate market reaction depends on the financial results and webcast discussion.

Related Companies

MDGL
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two hours after the live webcast. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com. Investor ContactTina Ventura, IR@madrigalpharma.com Media ContactChristopher Frates, media@madrigalpharma.com

Related News